Close Menu

NEW YORK – ProteinLogic has developed an immune system biomarker signature and predictive models that are part of a blood-based diagnostic test the firm anticipates launching to screen for active tuberculosis at the point of need.

The test, ImmiPrint-TB, conducts quantitative measurements of selected proteins and uses those values as inputs for predictive models derived using machine learning. The models, in turn, produce a diagnosis that reflects the presence or absence of TB.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.